Questions We Get Asked Often

A surgeon-led orthopedic longevity practice. Dr. Rahman — a board-certified orthopedic surgeon fellowship-trained at Kerlan-Jobe — delivers the clinical decision-making. The modality-intensive components (laser, photobiomodulation, shockwave, TECAR, soft tissue work) are delivered through our co-located clinical partnership with Dr. Michael Sheps, D.C., in Brentwood. We are not a wellness clinic, not a medspa, and not an à la carte biologics outlet. We are a focused orthopedic operation built around structured programs.

No. Dr. Rahman's insurance-based surgical practice — arthroscopy, joint reconstruction, cartilage restoration — runs through omarrahmanmd.com, with locations in Los Angeles and Covina. Chronos is his cash-pay orthopedic longevity practice focused on the decade before surgery, structured recovery, and the biology of resilience. Patients routinely move between both practices when that is what the situation calls for.

West Los Angeles, at Pacific Coast Sports Medicine (11710 Wilshire Boulevard, Brentwood), where consultation and cellular optimization take place, co-located with Dr. Rahman's office.

Chronos is a cash-pay practice. Patients seeking insurance-based orthopedic surgical care should be seen through Dr. Rahman's surgical practice at omarrahmanmd.com.

There are two ways to start. The Initial Consultation ($250) is the front door for anyone — a specific joint or tendon problem, or a question about peptides, orthobiologics, and recovery. The Longevity Consultation ($500) is the deeper, more comprehensive visit for patients focused on long-term optimization. Either consultation fee credits toward enrollment within 90 days. Programs are customized and typically range from $1,000 to $6,000 depending on scope; membership starts at $299 per month. All pricing is reviewed directly with you before any enrollment.

No. This website is educational and does not offer, advertise, or sell any specific compound. The Longevity Consultation is a clinical and educational conversation — what the evidence shows, what remains investigational, what the current regulatory picture looks like, and what informed consent means. Many compounds people ask about (including BPC-157, TB-500, TB-4, and MOTS-c) are not FDA-approved for human use, and their regulatory status shifts frequently. Any clinical decision is made individually with Dr. Rahman when it is clinically appropriate — never promised in advance and never on a web page.

BPC-157 is not FDA-approved for human use. It was previously placed in Category 2 of the FDA's 503A interim bulk drug substances list; it has since been removed from Category 2, and its status remains under active review and discussion by the Pharmacy Compounding Advisory Committee (PCAC). BPC-157 has also been added to the World Anti-Doping Agency (WADA) prohibited list, which matters for anyone subject to anti-doping testing. The regulatory picture continues to evolve, and it is reviewed in every consultation before anything is discussed clinically.

Two reasons. First, products sold online are unregulated — you have no way to verify the identity, purity, or dose of what is in the vial, and the FDA has issued repeated warnings about them. Second, the underlying clinical picture matters more than any protocol. Whether a compound is even worth considering depends on what tissue is involved, what your imaging shows, your training load, and your systemic health. A surgeon who can read your MRI gives you a far more honest read than an anonymous vendor and a YouTube video — including, often, the answer that a given approach is not supported by the evidence.

Not required, but helpful if you have it. Recent labs, imaging, and prior injection records can make the conversation more productive. If bloodwork is needed to move a plan forward, we will tell you exactly what to order and where.

All growth hormone secretagogues (ipamorelin, CJC-1295, tesamorelin, sermorelin) are prohibited under the World Anti-Doping Agency code. MOTS-c was added to the prohibited list in 2024. BPC-157 has been added to the WADA prohibited list. If you are subject to anti-doping testing, bring that context to the consultation — we will work within your competitive eligibility, not around it.

These are FDA-approved for type 2 diabetes and weight management, and there is a growing body of research on their effects in inflammation, cardiovascular risk, and joint loading — all directly relevant to orthopedic outcomes. If you are on a GLP-1 and are considering orthopedic surgery, discontinuation timing matters: these medications delay gastric emptying and can increase aspiration risk under anesthesia. We coordinate that with your prescriber and your surgical team.

We discuss the research landscape around allogeneic cellular products — Wharton's Jelly, umbilical cord–derived mesenchymal stem cells, and exosomes — and where the evidence actually sits. We do not oversell these products. Current science suggests mesenchymal stem cells do not meaningfully regrow cartilage when injected; the effect, if there is one, appears to be signaling rather than structural regeneration. Anyone promising cartilage regeneration from a stem cell injection is overselling what the evidence supports. We also discuss autologous (your own) approaches — including hair-follicle–derived mesenchymal stem cell secretome and personal cell banking through our partnership with Acorn — reviewed individually and under informed consent.

The Initial Consultation is the orthopedic entry point — a focused evaluation of a specific joint or tendon problem, with a program recommendation as the output. The Longevity Consultation is the systemic-health entry point — a conversation about peptides, metabolic optimization, and recovery biology. In practice, patients tend to fall into two groups: those coming in about a specific joint or tendon, and those focused on long-term optimization. The Longevity Consultation is the deeper, more comprehensive conversation — peptides, metabolic health, recovery biology, and long-term planning — while the Initial Consultation is the focused entry point for a specific problem. Many patients do both in the same visit. If you are not sure which to book, book the Initial Consultation and we will route you correctly.

The Joint Longevity Program runs three to six months. The Tendon Optimization Program runs eight to twelve weeks. The Post-Op Recovery Program runs for the duration of the surgical recovery arc. Every program has defined phases — assessment, intervention, reintegration — with milestone check-ins tied to your participation target.

Those are tools. Chronos is a system. Depending on your tissue picture and participation target, the plan may include high-dose PRP, peptide and emerging orthobiologic guidance, modality sequencing, and structured reintegration. None of these is a standalone treatment. Each is a component of a single therapeutic plan.

No. Our patients are active adults, typically 30–70, who want to keep participating in the things that matter to them — skiing, tennis, golf, surfing, long rides, hiking, or simply walking without pain. The question is whether you have a participation target that a structured plan can be built around. If you do, we can help.

Most patients transition into membership — quarterly reassessments, monthly modality care, seasonal pre-conditioning, and ongoing peptide/longevity guidance at member pricing. Membership is where the plan keeps working over time. It is not required; some patients complete a program and return only when they need another cycle of structured care.

The decision is not binary and it is not made by a website. It depends on whether your problem is mechanical (a torn structure that will not heal on its own) or biological (a tissue that is unhealthy but structurally intact), and where on that spectrum you sit. Read the full framework here. In a consultation, we look at the tissue, the mechanics, and the participation target together — and the plan is built from all three.

Three common reasons. First: a second opinion from a board-certified orthopedic surgeon active in regenerative research. Second: the months around your surgery — the prehabilitation window and the recovery window — are rarely managed with the structure they deserve. We add that structure. Third: if the answer is "not yet surgical," most practices do not have a plan for that phase. We do.

No. When surgery is the right answer, we say so — and we can do the operation ourselves through Dr. Rahman's surgical practice or refer you to the right specialist. Our entire model depends on being honest about when the mechanical answer is the right answer. That honesty is the brand.

In-person is preferred for an orthopedic evaluation — examination and ultrasound matter. Telemedicine is available for imaging review, second-opinion consultations, peptide/longevity discussions when appropriate, and initial triage.

Any recent imaging (MRI, X-ray, ultrasound — on disc or accessible via portal), a list of current medications and supplements, prior injection records if you have had any, and your training or activity log if you keep one. If you have a specific participation target (an event, a season, a race), bring the date.

New-patient consultations are typically scheduled within one to two weeks. Urgent evaluations — an acute injury, a second-opinion on an imminent surgical decision — are accommodated as quickly as scheduling allows. Members have 48-hour priority scheduling for flare-ups.

Request a consultation here. A member of the team will follow up within one business day to confirm scheduling and review any preparatory imaging or records to bring.